L&G Pharma Breakthrough UCITS ETF | BIOT

Registrer dig for at låse op for ratings
Fondens performance30-04-2024
Vækst af 1.000 (DKK) Avanceret graf
L&G Pharma Breakthrough UCITS ETF
          | 
          BIOT
Fond17,23,6-2,4-12,2-8,8
+/-Kat-1,56,710,4-13,5-6,4
+/-Indeks-8,1-3,20,6-22,3-16,8
 
Oversigt
Closing Price
10-05-2024
 USD 9,71
Kursændring 1 dag -0,12%
Morningstar Kategori™ Sektor - Bioteknologi, Aktier
Omsætning 1827
Børs LONDON STOCK EXCHANGE, THE
ISIN IE00BF0H7608
Markedsværdi i alt (mio.)
10-05-2024
 USD 18,78
Seneste TNA(mio.)
10-05-2024
 USD 18,78
Løbende omkostning
14-02-2024
  0,49%
Investeringsstrategi Passiv
Investeringsmålsætning: L&G Pharma Breakthrough UCITS ETF | BIOT
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
Returns
Løbende afkast10-05-2024
År til dato-5,34
3-år ann.-3,89
5-år ann.1,48
10-år ann.-
12 mdrs. udbytte i pct. 0,00
Management
Manager navn
Startdato
-
-
Startdato
18-01-2018
Annonce
Kategoribenchmark
Fondens indeksMorningstar indeks
Solactive Pharma Breakthrough V NR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreIkke specifik
ComponentIkke specifik
AndetIkke specifik
Primary Objective
BevarelseNej
VækstJa
IndkomstNej
HedgingIkke specifik
AndetJa
Formuefordeling  L&G Pharma Breakthrough UCITS ETF | BIOT10-05-2024
Morningstar stylebox®
Aktiestil
Aktivfordeling
  % Lang% Kort% Netto
Aktier99,950,0099,95
Obligationer0,000,000,00
Kontant o. lign.0,050,000,05
Andet0,000,000,00
Top 5 regioner%
USA39,83
Japan19,59
Europa - ex Euro-lande12,27
Asien - Nye markeder10,47
Eurolande10,20
Top 5 sektorer%
Healthcare100,00
Top 5 placeringerSektor%
SciClone Pharmaceuticals (Holdin... HealthcareHealthcare3,28
AstraZeneca PLC ADRHealthcareHealthcare2,85
Ipsen SAHealthcareHealthcare2,80
United Therapeutics CorpHealthcareHealthcare2,72
Pharma Mar SAHealthcareHealthcare2,58
L&G Pharma Breakthrough UCITS ETF | BIOT

Related

For at sikre konsistens på tværs af data leveret fra forskellige kapitalforvaltere, generes de beregnede datapunkter ved hjælp af Morningstars proprietære beregningsmetode, der beskrives mere detaljeret her(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Brugervilkår        Fortrolighedspolitik        Cookie Settings        Offentliggørelser